Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.

J Invest Dermatol. 2014 Jan;134(1):229-236. doi: 10.1038/jid.2013.279. Epub 2013 Jun 21.

2.

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Benoit BM, Jariwala N, O'Connor G, Oetjen LK, Whelan TM, Werth A, Troxel AB, Sicard H, Zhu L, Miller C, Takeshita J, McVicar DW, Kim BS, Rook AH, Wysocka M.

Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.

PMID:
27766406
3.

The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.

Bernengo MG, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, Cappello N, Fierro MT.

Br J Dermatol. 2001 Jan;144(1):125-35.

PMID:
11167693
4.

Expression of CD164 on Malignant T cells in Sézary Syndrome.

Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, Navarini AA, Mitev V, Dummer R, Kazakov DV, French LE, Hoetzenecker W, Cozzio A.

Acta Derm Venereol. 2016 May;96(4):464-7. doi: 10.2340/00015555-2264.

5.

Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome.

Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Steitz J, Roszkiewicz J, Bieber T, Tüting T.

Clin Exp Dermatol. 2005 Nov;30(6):702-6.

PMID:
16197392
6.

The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.

Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C, Limas K, Stratigos A, Stavrianeas N, Avgerinou G, Katsambas A.

Br J Dermatol. 2003 Apr;148(4):709-18.

PMID:
12752128
7.

Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.

Zaki MH, Shane RB, Geng Y, Showe LC, Everetts SE, Presky DH, Wysocka M, Moore JS, Rook AH.

J Invest Dermatol. 2001 Jul;117(1):119-27.

8.

The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.

Scala E, Abeni D, Pomponi D, Narducci MG, Lombardo GA, Mari A, Frontani M, Picchio MC, Pilla MA, Caprini E, Russo G.

Haematologica. 2010 Nov;95(11):1905-12. doi: 10.3324/haematol.2010.026260. Epub 2010 Jul 27.

9.

Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.

Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, Abuzahra F, Bowman E, Roszkiewicz J, Bieber T, Tüting T.

Br J Dermatol. 2005 Feb;152(2):258-64.

PMID:
15727636
10.

Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.

Cedeno-Laurent F, Wysocka M, Obstfeld AE, Novoa RA, Vittorio CC, Kim EJ, Weng WK, Rook AH.

J Cutan Pathol. 2017 May;44(5):462-466. doi: 10.1111/cup.12899. Epub 2017 Feb 10.

PMID:
28083948
11.

Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.

Harmon CB, Witzig TE, Katzmann JA, Pittelkow MR.

J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):404-10.

PMID:
8784277
12.

Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.

Hristov AC, Vonderheid EC, Borowitz MJ.

Am J Clin Pathol. 2011 Dec;136(6):944-53. doi: 10.1309/AJCP09OTJOYAVZZK.

PMID:
22095381
13.

Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.

Samimi S, Benoit B, Evans K, Wherry EJ, Showe L, Wysocka M, Rook AH.

Arch Dermatol. 2010 Dec;146(12):1382-8. doi: 10.1001/archdermatol.2010.200. Epub 2010 Aug 16.

14.

Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.

Jones CL, Ferreira S, McKenzie RC, Tosi I, Caesar JA, Bagot M, Whittaker SJ, Mitchell TJ.

J Invest Dermatol. 2012 Aug;132(8):2042-9. doi: 10.1038/jid.2012.106. Epub 2012 Apr 12.

15.

Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.

Wechsler J, Bagot M, Nikolova M, Parolini S, Martin-Garcia N, Boumsell L, Moretta A, Bensussan A.

J Pathol. 2003 Jan;199(1):77-83.

PMID:
12474229
16.

Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma.

Fierro MT, Novelli M, Quaglino P, Comessatti A, Fava P, Ortoncelli M, Ponti R, Bernengo MG.

Dermatology. 2008;216(3):213-21. doi: 10.1159/000112928. Epub 2008 Jan 9.

PMID:
18182812
17.

Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.

Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH.

J Am Acad Dermatol. 2005 Sep;53(3):428-34.

PMID:
16112348
18.

CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.

Moins-Teisserenc H, Daubord M, Clave E, Douay C, Félix J, Marie-Cardine A, Ram-Wolff C, Maki G, Beldjord K, Homyrda L, Michel L, Bensussan A, Toubert A, Bagot M.

J Invest Dermatol. 2015 Jan;135(1):247-257. doi: 10.1038/jid.2014.356. Epub 2014 Aug 26.

19.

CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.

Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, Reinhold U.

J Am Acad Dermatol. 2001 Mar;44(3):456-61.

PMID:
11209115
20.

Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets.

Willheim M, Ebner C, Baier K, Kern W, Schrattbauer K, Thien R, Kraft D, Breiteneder H, Reinisch W, Scheiner O.

J Allergy Clin Immunol. 1997 Sep;100(3):348-55.

PMID:
9314347

Supplemental Content

Support Center